Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
Dateline City:
KENILWORTH, N.J.
Data from Pivotal Phase 3 KEYNOTE-204 Study to be Presented at an Upcoming Medical Meeting and Submitted to Regulatory Authorities
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 KEYNOTE-204 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) met one of its dual primary endpoints of progression-free survival (PFS).
Language:
English
Contact:
Media Contacts:
Pamela Eisele
(267) 305-3558
Claire Gillespie
(267) 305-0932
Investor Contacts:
Peter Dannenbaum
(908) 740-1037
Raychel Kruper
(908) 740-2107
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck
